PropThink: QCOR Delivers Big Upside In 3Q; Acthar Prescribing & Reimbursement Remain In-Tact

PropThink: QCOR Delivers Big Upside In 3Q; Acthar Prescribing & Reimbursement Remain In-Tact

[ACN Newswire] – By David MoskowitzQuestcor Pharmaceuticals (NASDAQ:QCOR) trounced 3Q 2012 earnings expectations, with reported revenues of $140.3M and adjusted EPS of $0.97 for the period. This compares to Wall Street … more

View todays social media effects on QCOR

View the latest stocks trending across Twitter. Click to view dashboard

Share this post